GPRC5D and neoplasm: GPRC5D is highly expressed in malignant plasma cells, and the GPRC5D × CD3 bispecific antibody, JNJ-64407564, demonstrated potent antigen-specific T-cell–mediated cytotoxicity against myeloma cells in vitro and induced tumor regression in xenograft models [21].